search
Back to results

The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

Primary Purpose

Schizophrenia

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Risperidone
Olanzapine
Quetiapine
Aripiprazole
Ziprasidone
Sponsored by
Shanxi Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Schizophrenia

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Unrelated Han Chinese recruited from the north of China.
  • Drug-free for at least one month before enrollment.
  • Clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for SZ (American Psychiatric Association, 1994), relying on the Chinese Version of the Modified Structured Clinical Interview for DSM-IV TR Axis I Disorders Patient Edition (SCID-I/P,11/2002 revision).

Exclusion Criteria:

  • Pregnant or had significant medical conditions.
  • Unstable psychiatric features (e.g., suicidal feelings).
  • A history of substance abuse or drug addiction within the previous 6 months, with the exception of nicotine dependence.
  • Other Axis I co-morbid disorders were not excluded.

Sites / Locations

  • First Clinical Medical College of Shanxi Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

antipsychotics

health control

Arm Description

This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.

This group was treated with no invention

Outcomes

Primary Outcome Measures

Number of schizophrenics with antipsychptic treatment who achieved remission assessed by PANSS.
The clinical effects were assessed by trained and experienced psychiatrists with the Positive and Negative Syndrome Scale (PANSS) before and after 12-week treatment.

Secondary Outcome Measures

Full Information

First Posted
January 6, 2016
Last Updated
January 7, 2016
Sponsor
Shanxi Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT02650102
Brief Title
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
Official Title
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2013 (undefined)
Primary Completion Date
December 2016 (Anticipated)
Study Completion Date
December 2016 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanxi Medical University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aberrant expression of micro-RNAs (miRNAs) has been described in many human diseases, including schizophrenia (SZ). The previous work has indicated a strong genetic association between the miRNA-30e precursor (pre-miR-30e) and the risk of SZ. However, to date, few reports have focused on the expression level of the miR-30 family (miR-30s) and its networks of co-regulation in SZ, even in response to antipsychotic treatment. Given this, the investigator first constructed a hybrid miRNA-TF (transcription factor)-gene-PPI (protein-protein interactions) network focusing on miR-30s by bioinformatics technology. The investigator then selected several candidate miR-30s and key regulators for further validation. These candidates were then quantified by real-time quantitative PCR (qRT-PCR) in an independent cohort of 200 healthy controls and 200 drug-free SZ patients, among which were followed up by 12-week antipsychotic treatment. Furthermore, the investigator evaluated the correlation between the change in gene expression and the improvement of symptoms.
Detailed Description
Schizophrenia is one of the most serious mental disorder,which is characterized by high prevalence rate ,high recurrence rate, could increase patients' disability and burden of disease. But the pathological mechanism is so far unknown. Until recently, more attention are focused on gene dysregulation hypothesis. The preliminary works of our laboratory prompted that microRNA-30e gene polymorphism and expression abnormal may be related to schizophrenia. Combined with previous studies showed that miRNA disorder involved in neurodevelopmental obstacle and neuropsychiatric disease, the investigators surmised: miR-30e dysregulation can impact the occurrence and development of schizophrenia. This study will carry on the multidimensional research by using the technology of neurobiology, molecular genetics,neuroimaging and so on, and integrate methods of molecular, cell, animal and human body tracking, so as to:(1) Explaining the transcription and regulation mechanisms of target genes of miR-30e,and building the gene regulatory network of schizophrenia as the core of miR-30e.(2)To investigate the pathogenesis of miR-30e participate in schizophrenia, and to evaluate the clinical value of miR-30e in peripheral blood on the disease diagnose, genotyping, predicting efficacy and ending. The object of this study is to provide new scientific data and research ideas for further exploring the neurobiological basis of schizophrenia, and recognize pathophysiological mechanisms of schizophrenia, ultimately to improve and strengthen the new situation in schizophrenia prevention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
antipsychotics
Arm Type
Experimental
Arm Description
This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.
Arm Title
health control
Arm Type
No Intervention
Arm Description
This group was treated with no invention
Intervention Type
Drug
Intervention Name(s)
Risperidone
Other Intervention Name(s)
Risperdal
Intervention Description
a kind of antipsychotics
Intervention Type
Drug
Intervention Name(s)
Olanzapine
Other Intervention Name(s)
Zyprexa
Intervention Description
a kind of antipsychotics
Intervention Type
Drug
Intervention Name(s)
Quetiapine
Other Intervention Name(s)
Seroquel
Intervention Description
a kind of antipsychotics
Intervention Type
Drug
Intervention Name(s)
Aripiprazole
Other Intervention Name(s)
Abilifya
Intervention Description
a kind of antipsychotics
Intervention Type
Drug
Intervention Name(s)
Ziprasidone
Other Intervention Name(s)
Geodon
Intervention Description
a kind of antipsychotics
Primary Outcome Measure Information:
Title
Number of schizophrenics with antipsychptic treatment who achieved remission assessed by PANSS.
Description
The clinical effects were assessed by trained and experienced psychiatrists with the Positive and Negative Syndrome Scale (PANSS) before and after 12-week treatment.
Time Frame
Number of schizophrenics with 12-week antipsychptic treatment who achieved remission assessed by PANSS.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Unrelated Han Chinese recruited from the north of China. Drug-free for at least one month before enrollment. Clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for SZ (American Psychiatric Association, 1994), relying on the Chinese Version of the Modified Structured Clinical Interview for DSM-IV TR Axis I Disorders Patient Edition (SCID-I/P,11/2002 revision). Exclusion Criteria: Pregnant or had significant medical conditions. Unstable psychiatric features (e.g., suicidal feelings). A history of substance abuse or drug addiction within the previous 6 months, with the exception of nicotine dependence. Other Axis I co-morbid disorders were not excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yong Xu, Doctor
Phone
18234016125
Email
xuyongsmu@vip.163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yong Xu, Doctor
Organizational Affiliation
Shanxi Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
First Clinical Medical College of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yong Xu, Doctor
Phone
18234016125
Email
xuyongsmu@vip.163.com
First Name & Middle Initial & Last Name & Degree
Sha Liu, Doctor
Phone
15803400167
Email
liusha1984114@163.com

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

We'll reach out to this number within 24 hrs